|1.||Gualberto, Antonio: 5 articles (05/2009 - 03/2005)|
|2.||Haluska, Paul: 3 articles (05/2009 - 06/2007)|
|3.||Sharma, Amarnath: 2 articles (07/2008 - 10/2007)|
|4.||Yin, Donghua: 2 articles (07/2008 - 10/2007)|
|5.||de Bono, Johann S: 2 articles (10/2007 - 06/2007)|
|6.||Prous, J R: 2 articles (09/2007 - 06/2007)|
|7.||Rabasseda, X: 2 articles (09/2007 - 06/2007)|
|8.||Koumenis, Constantinos: 1 article (07/2011)|
|9.||El-Deiry, Wafik S: 1 article (07/2011)|
|10.||Christensen, James G: 1 article (07/2011)|
03/01/2005 - "The extent of IGF-1R down-regulation in vivo was proportional to CP-751,871 concentrations in the serum of tumor-bearing mice. "
08/15/2009 - "Finally, combination therapy with CP-751,871 and radiation delayed the growth of NSCLC tumor xenografts in nude mice to a greater extent than did either treatment modality alone. "
08/15/2009 - "The radiosensitizing effect of CP-751,871 was evaluated on the basis of cell death, clonogenic survival, and progression of tumor xenografts. "
07/15/2011 - "CP-751,871 reduces CSC populations in colon cancer cell lines in vitro and reduces tumor growth in vivo. "
07/15/2011 - "CP-751,871, a fully human antibody with specificity to the IGF-1 receptor, is currently being tested in clinical trials for a variety of solid tumors. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/15/2009 - "We have now investigated the effect of CP-751,871, a fully human monoclonal antibody specific for IGF-IR, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to radiation. "
08/15/2009 - "Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells."
05/20/2009 - "We conducted a phase II study of combination of the anti-insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in advanced treatment-naïve non-small-cell lung cancer (NSCLC). "
05/20/2009 - "Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer."
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/2007 - "Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]"
07/01/2008 - "Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma."
07/01/2008 - "These data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma."
07/01/2008 - "After informed consent and screening, 47 patients with multiple myeloma in relapse or refractory phase were enrolled into 11 dose-escalation cohorts of CP-751,871 at doses from 0.025 to 20 mg/kg for 4 weeks. "
|2.||IGF Type 1 Receptor (IGF 1 Receptor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)